Neos Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported Net product sales were $10,729,000 compared to $5,631,000 a year ago. Net loss was $14,436,000 or $0.50 per basic and diluted share compared to $17,221,000 or $0.88 per basic and diluted share a year ago. Loss from operations was $12,518,000 compared to $15,088,000 a year ago.

The company expects its revenue prescript could increase to $120 to $130 range for Adzenys by the end of 2018 and will be approaching for $100 for Cotempla in the fourth quarter. The company plans to spend roughly $0.25 million -- around $250,000, and that will probably be fairly evenly spread throughout the year. It's still within the overall guidance the company had given for R&D spend for this year 2018.